Phase 1 Study of a Recombinant Mutant Protective Antigen of Bacillus anthracis

A phase 1 study of a recombinant mutant protective antigen (rPA) vaccine was conducted in 186 healthy adults aged 18 to 45 years. Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-μg dosages each, or the licensed vaccine,...

Full description

Saved in:
Bibliographic Details
Main Authors: Bellanti, Joseph A., Lin, Feng-Ying C., Chu, Chiayung, Shiloach, Joseph, Leppla, Stephen H., Benavides, German A., Karpas, Arthur, Moayeri, Mahtab, Guo, Chunyan, Robbins, John B., Schneerson, Rachel
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2012
Subjects:
Vaccines
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272932/
https://ncbi.nlm.nih.gov/pubmed/22190398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.05556-11
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items